Increased Umbilical Cellular Fibronectin Concentrations Are Associated With a Decreased Prevalence of Growth Restriction in Preeclampsia

Abstract

Objective: Cellular fibronectin (cFN), a marker of endothelial activation, is elevated in maternal and cord blood in preeclampsia. We tested whether maternal or fetal cFN is related to fetal growth restriction in preeclampsia, in the context of gestational age at delivery.

Methods: Cellular fibronectin was measured in maternal and cord blood of 29 preeclamptic women and their infants delivered at Magee-Womens Hospital at 25-41 weeks of gestation. Relationships amog maternal and cord cFN, birth weight, birth weight percentile, and ponderal index were evaluated using Pearson correlation and regression analyses controlled for gestational age.

Results: Cord cFN was not significantly related to maternal cFN (r = -.34, P = .08) or gestational age (r = -.32, P = .09). The relationship of maternal cFN to each index of infant size was not significant. By contrast, higher cord cFN predicted higher birth weight, birth weight percentile, and ponderal index (P < .05).

Conclusion: Elevated maternal and cord cFN concentrations have been reported in pregnancy complicated by preeclampsia. This study assessed the relationship among maternal cFN, cord cFN, and indices of fetal growth in preeclampsia. Elevated cord cFN was associated with measures of better fetal growth.

Keywords

Preeclampsia cellular fibronectin endothelial activation fetal growth intrauterine growth restriction

Get full access to this article

View all access options for this article.

References

1. Roberts JM , Redman CW . Pre-eclampsia: More than pregnancy-induced hypertension. Lancet 1993;341:1447-1451.

2. Friedman SA , De Groot CJM , Taylor RN , Golditch BD , Roberts JM . Plasma cellular fibronectin as a measure of endothelial involvement in preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1994;170:838-841.

3. Peters JH , Maunder RJ , Woolf AD , Cochrane CG , Ginsberg MH . Elevated plasma levels of ED1+ (“cellular”) fibronectin in patients with vascular injury. J Lab Clin Med 1989;113:586-597.

4. Davidge ST , Signorella AP , Lykins DL , Gilmour CH , Roberts JM . Evidence of endothelial activation and endothelial activators in cord blood of infants of preeclamptic women. Am J Obstet Gynecol 1996;175:1301-1306.

5. Metcoff J . Clinical assessment of nutritional status at birth: Fetal malnutrition and SGA are not synonymous. Pediatr Clin North Am 1994;41:875-891.

6. Murphy-Ullrich JE , Mosher DF . Fibronectin and Disease Processes. In: Uitto J , Perejda AJ , eds. Connective tissue disease: molecular pathology of the extracellular matrix. New York: Marcel Dekker, 1986;455-473.

7. Friedman SA , Schiff E , Emeis JJ , Dekker GA , Kao L , Sibai BM . Fetal plasma levels of cellular fibronectin as a measure of fetal endothelial involvement in preeclampsia. Obstet Gynecol 1997;89:46-48.

8. de Jager CA , Shephard EG , Robson SC , Jaskiewicz K , Froese S , Anthony J , et al. Degradation of fibronectin in association with vascular endothelial disruption in preeclampsia. J Lab Clin Med 1995;125:522-530.

9. Walther FJ , Ramackers LHJ . The Ponderal Index as a measure of the nutritional status at birth and its relation to some aspects of neonatal morbidity. J Perinat Med 1982;10:42-47.

10.

10. Kramer MS , McLean FH , Olivier M , Willis DM , Usher RH . Body proportionality and head and length `sparing' in growth-retarded neonates: A critical reappraisal. Pediatrics 1989;84:717-723.

11.

11. Haig D . Genetic conflicts in human pregnancy. Q Rev Biol 1993;68:495-532.